<DOC>
	<DOCNO>NCT02420730</DOCNO>
	<brief_summary>This study examine safety , tolerability , systemic pharmacokinetics 3 different concentration AGN-232411 topical ophthalmic solution healthy participant participant dry eye .</brief_summary>
	<brief_title>Safety , Tolerability Systemic Pharmacokinetics AGN-232411 Healthy Participants Participants With Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Inclusion criterion : Stage 1 Healthy participant . Stage 2 Participants symptoms dry eye disease . Exclusion criterion : Stage 1 Known allergy sensitivity study medication , fluorescein , lissamine green Stage 2 Known allergy sensitivity study medication , fluorescein , lissamine green Allergic ocular disease , ocular trauma , corneal erosion ulcer , uveitis within previous 12 month History ocular surgery within previous 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>